Navigation Links
Small Animal Imaging Market: Biospace Lab Wins Frost & Sullivan Accolade for Its Successful Product Line Strategy

LONDON and PARIS, Oct. 1 /PRNewswire/ -- The 2008 Frost & Sullivan European Preclinical Small Animal Imaging Product Line Strategy of the Year Award is presented to Biospace Lab for keeping abreast of market requirements with its strong product portfolio. The company's outstanding product line has allowed it to attract new customers while satisfying existing ones, leading to increased market share.

"An in-depth understanding of, and ability to respond to, end user requirements supported by robust research and development efforts have yielded an expanding customer base," notes Frost & Sullivan Research Analyst Santhosh Kumar Ramaraj. "The company's strong product portfolio has laid a firm foundation for the company's continued growth."

"It is a great honour for Biospace Lab to get this Award based on a thorough and impartial market research and analysis conducted by Frost & Sullivan," said Bruno Brisson, Biospace Lab's CEO. He added, "This is recognition of our unique position in the preclinical small animal imaging market with a strategically positioned product line covering different modalities that fulfils customer needs and expectations from in vitro to in vivo imaging."

Biospace Lab offers a wide range of in vitro and in vivo imaging products. The Photon Imager(TM), a real time bioluminescence and fluorescence system, dynamically detects and quantifies the optical signal. With the In Actio(TM) add-on, anesthesia is no longer required. The Photon Imager uses a technology developed for night vision and is faster and more sensitive than most of its competitors.

Gamma Imager allows easy switching from planar scintigraphy to Micro-SPECT and Micro-SPECT/CT, with a good price to quality ratio. Beta Microprobe is an alternative to Micro-PET for local pharmacokinetics measurements with a simple, cost-effective system. Biospace Lab's in vivo imaging products are thus well suited for the imaging of molecular, metabolic, physiologic as well as anatomical events in small animals.

The autoradiography solution includes Beta Imager and Micro Imager, which are marked by sensitivity and speed. They are applied in the accurate detection, localisation and quantification of radio-labeled molecules in tissue sections for various protocols (including pharmacokinetics, receptor binding studies and anatomical studies) in various fields such as neurology, microbiology and oncology.

"Biospace Lab values quality and its systems are thoroughly tested during the production process," states Ramaraj. "Its commitment to product innovation -- the latest being the In Actio(TM) module in Photon Imager that gives users the unique capability to perform imaging on non-anesthetised animals -- has effectively met evolving customer needs."

Most Biospace Lab's competitors have a restricted product range that fails to meet diverse end user requirements. For instance, animal optical imaging system providers are limited solely to the optical imaging segment. In contrast, Biospace Lab has a robust product portfolio offering optical imaging- scintigraphy - autoradiography, thus accommodating the different market segments within the small animal imaging market.

Biospace Lab has demonstrated strong penetration of vertical markets with its autoradiography solutions. The device holds particular appeal for pharmaceutical companies since the characteristics of the device meet perfectly the needs for drug development imaging such as speed, sensitivity and repeatability.

"The company has focused primarily on developing advanced, high quality products that offer exceptional customer value," comments Ramaraj. "Biospace Lab now has the capacity to fully support its varied and ever expanding client base in their search for imaging solutions relevant to their needs in different conditions."

The Frost & Sullivan Product Line Strategy of the Year Award is presented each year to the company that has demonstrated the most insight into the needs and product demands of its customers. The recipient company has optimized its product line by leveraging products with the various price, performance, and feature points required by one or more market segments.

Frost & Sullivan Best Practices Awards recognise companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research in order to identify best practices in the industry.

About Biospace Lab:

Biospace was founded in 1989 by Nobel Prize winner Dr. Georges Charpak to provide fellow researchers in biology with innovative imaging tools based on his discoveries in high-energy physics and particle detection. Since then, Biospace has pursued and created strong links with the medical, pharmaceutical and scientific communities to bring relevant and creative solutions to biomedical imaging needs with the split of two independent companies.

Biospace lab ( focuses on high-performance imaging equipment for pre-clinical research in drug discovery and biology. The company has developed in this field a comprehensive portfolio of in vitro, in vivo and now in actio(R) multimodality small animal imaging solutions used by almost every major pharmaceutical company and many prestigious academic centers worldwide.

Biospace Lab headquarters, development and production facilities are located in central Paris, France and the company has a subsidiary in Cambridge, MA USA.

Biospace Lab USA, 185 Alewife Brook Parkway, Suite 410,

Cambridge, MA 02138,

t (909) 938-9470, f (909) 982-3034

Biospace Lab, 10 rue Mercoeur,

Paris, France 75011,

t +33 (0) 1 55 25 60 60, f +33 (0) 1 55 25 60 61

About Frost & Sullivan:

Frost & Sullivan, the Growth Partnership Company, partners with clients to accelerate their growth. The company's TEAM Research, Growth Consulting and Growth Team Membership(TM) empower clients to create a growth-focused culture that generates, evaluates and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 30 offices on six continents. For more information about Frost & Sullivan's Growth Partnerships, visit

Media Contact:

Ciara Jamie Connolly, Senior Events & Promotions Executive, Best Practices, DDI: +44 (0) 207 915 7868, mailto:

SOURCE Frost & Sullivan
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Imagenetix Inc. to Present at Noble Small Cap Financial Conference on August 21, 2007
2. FDA Approves ACAM2000(TM) Vaccine for Protection Against Smallpox
3. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
4. Stimuvax(R) Phase II data highlight three-year survival results for patients with non-small cell lung cancer
5. New technique producing small things in large quantities
6. Small Bone Innovations Introduces the Artelon(R) STT Spacer to Increase Treatment Options for Thumb Arthritis
7. Cell Therapeutics, Inc. (CTI) Receives SPA Approval from FDA and Launches Gender-Specific Phase III Trial for Advanced Non-Small Cell Lung Cancer
8. Small Bone Innovations Introduces New Distal Radius Plating System to Repair Complex Fractures
9. Cepheid to Present at William Blair Small-Cap Growth Stock Conference
10. Government Expands Trial With IMVAMUNE(R) Smallpox Vaccine in Persons With Atopic Dermatitis/Eczema
11. Poniard Pharmaceuticals Announces European Commission Grants Orphan Medicinal Product Designation to Picoplatin for Treatment of Small Cell Lung Cancer
Post Your Comments:
(Date:11/25/2015)... November 26, 2015 ... Market 2016 - 2020 report analyzes that automating ... and quality in long-term samples, minimizing manual errors, ... Automation minimizes manual errors such as mislabeling or ... Further, it plays a vital role in blood ...
(Date:11/25/2015)...  PharmAthene, Inc. (NYSE MKT: PIP) announced  today that ... plan (Rights Plan) in an effort to preserve the ... Section 382 of the Internal Revenue Code (Code). ... of its NOLs could be substantially limited if the ... 382 of the Code. In general, an ownership change ...
(Date:11/25/2015)... 25, 2015 2 nouvelles études permettent ... les différences entre les souches bactériennes retrouvées dans la ... des êtres humains . Ces recherches  ouvrent une nouvelle ... prise en charge efficace de l,un des problèmes ... chats .    --> 2 nouvelles études ...
(Date:11/25/2015)... 2015 Studies reveal the differences ... and pave the way for more effective treatment for one ...   --> --> ... problems in cats, yet relatively little was understood about the ... have been conducted by researchers from the WALTHAM Centre for ...
Breaking Biology Technology:
(Date:11/20/2015)... November 20, 2015 NXTD ) ... on the growing mobile commerce market and creator of ... Pereira , was recently interviewed on The RedChip ... on this weekend on Bloomberg Europe , Bloomberg ... --> NXTD ) ("NXT-ID" or the "Company"), ...
(Date:11/19/2015)... , Nov. 19, 2015  Based on its in-depth ... Sullivan recognizes BIO-key with the 2015 Global Frost & ... Frost & Sullivan presents this award to the company ... to the needs of the market it serves. The ... meets and expands on customer base demands, the overall ...
(Date:11/19/2015)... -- Although some 350 companies are actively involved in molecular ... according to Kalorama Information. These include Roche Diagnostics, Hologic, Abbott ... of the 6.1 billion-dollar molecular testing market, according to ... Diagnostic s .    ... one company and only a handful of companies can ...
Breaking Biology News(10 mins):